Identification of Blood Biomarkers for Bipolar Disorder using SERS and Explainable Machine Learning

11 December 2025, Version 1
This content is an early or alternative research output and has not been peer-reviewed by Cambridge University Press at the time of posting.

Abstract

The differentiation of bipolar disorder (BD) from major depressive disorder (MDD) represents a persistent challenge in psychiatry, leading to high rates of misdiagnosis and adverse patient outcomes. Objective biomarkers are critically needed, but their discovery is hampered by limited understanding of the disease etiology. Robust unbiased, hypothesis-free, and untargeted discovery methods combined with machine learning could prove valuable in providing diagnostic utility. In this study, a novel surface-enhanced Raman spectroscopy (SERS)-gold nanoparticle (AuNP)-cucurbit[5]uril (CB[5]) approach for biomarker discovery was applied for the first time in a clinical setting in combination with an explainable AI driven approach to distinguish BD from MDD. Dried blood spot (DBS) samples were collected from 130 patients with BD and MDD and analysed using SERS and AuNP-CB[5] aggregates. An XGBoost machine learning model was trained to differentiate the groups, with the Context Representative Interpretable Model Explanations (CRIME) method used to identify the most predictive spectral features. These features were subsequently correlated with metabolites measured using targeted mass spectrometry to identify underlying biomarkers. The model distinguished BD from MDD with an AUC of 0.66 (P = 0.003). The predictions were driven by two primary spectral peak regions identified through correlation analysis. The most important peak (1450 cm-¹) corresponded to hypoxanthine, which was significantly upregulated in the BD group. The link between hypoxanthine and the SERS signal was supported by experimental confirmation of correlated spectral peaks, validating the method’s specificity. This study validates a comprehensive DBS-SERS-AuNP-CB[5] clinical discovery pipeline, establishing a powerful, unbiased framework that opens new avenues for developing point-of-care diagnostics for complex neuropsychiatric disorders and other conditions.

Keywords

SERS
bipolar disorder
major depressive disorder
biomarkers
dried blood spots
point-of-care testing
hypoxanthine

Supplementary materials

Title
Description
Actions
Title
Supplementary Materials for Identification of Blood Biomarkers for Bipolar Disorder using SERS and Explainable Machine Learning
Description
Supplementary Tables and Figures
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting and Discussion Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.